Mycoplasma Testing Market: Geographical Snapshot of the Market

Factors driving the growth of this market are the rapid growth in the pharmaceutical and biotechnology industries, R&D investments and government support. Mycoplasma testing is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the globe serves as a direct driver for associated markets such as mycoplasma testing.

The Mycoplasma Testing Market is expected to reach USD 943.4 Million by 2022 from USD 523.3 Million in 2017, at a CAGR of 12.5%.

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856

On the basis of products, the mycoplasma testing market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to dominate the global mycoplasma testing market in 2017. The frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques are key factors driving the growth of this segment.

Based on technique, the mycoplasma testing market is segmented into PCR, ELISA, direct assays, indirect assays, DNA staining, microbial culture techniques, and enzymatic methods. In 2017, the PCR technique segment is expected to account for the largest share of the mycoplasma testing market, by technique. The high acceptance rate of PCR due to the accuracy, speed, and flexibility provided by this technique in life sciences research is one of the major factors driving this segment.

Based on region, the mycoplasma testing market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the mycoplasma testing market in 2017 on account of the high adoption rate of novel technologies and a large number of life science research studies conducted in this region.

Speak To Analyst: -https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=136509856

Key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.) and  Bionique Testing Laboratories, Inc. (U.S.).

4 Reasons Why E-commerce Websites Should Be Equipped with A Mobile App

 A majority of consumers choose to buy digitally now, rather than visit local shops—and this trend has only been helped by the COVID-19 pandemic. Since online shopping systems are growing in prevalence and are cheaper than ever before, it is no wonder that more and more customers are deciding that they want to shop online and get their items shipped to their home or pick them up later at their closest store as per their convenience. E-commerce companies can leverage many techniques to boost user experience and increase total profits—a prominent one being to start an e-commerce mobile app for their online store. 

Here are a few reasons for e-commerce companies to have a mobile app: 

 

Read More: - https://www.360quadrants.com/software/e-commerce-platforms

 

Customer Comfort  

As more and more people are opting to use their smartphones or tablets while buying online, creating an app will help make their journey a bit simpler. Rather than using a website while shopping, mobile devices make it easy for consumers to locate and purchase the products they need through e-commerce mobile apps. Having an app would make things easy for clients and allow them to save user preferences, making repeat experiences much more appealing. 

 

Improved Competitiveness 

With online purchases gaining popularity and more online stores open than ever before, the biggest priority for e-commerce companies is to ensure they stay successful in the marketplace. Look to the biggest rivals for what they are doing – odds are they will have a smartphone device ready to access and use while shopping for their clients. Being the retailer that does not have a smartphone app might mean losing to the competition and being left behind. For more details about how to get going, consider contacting a vendor that will help create an app that outclasses competitors. 

 

Better Consumer Loyalty  

Developing a smartphone app will not only make it easy for clients to buy from the company; it will also make market analysis and consumer interaction simpler for the business. Through an app, monitoring the variety of items the consumers choose, together with the ones they browse at and express interest in, is far simpler irrespective of whether they execute the order or not. As a consequence, users will have more details on hand to use while giving the consumers tailor-made ideas for innovative goods, offers, and more than people know they would love. 

 

Better Explanation  

Finally, creating a mobile app ensures people will get more access to the business – the brand logo would be right there on the mobile and tablet screens of the clients, prompting them every moment they glance at their phones. In fact, email alerts will be used to inform the consumers on fresh goods, sales, and more through the e-commerce mobile app. 

 

Final Insights 

As more and more shoppers are now purchasing digitally via their apps, a fantastic smartphone app is a necessity for every smart e-commerce website. Mobile e-commerce apps can be the portal, helping businesses communicate with customers across the globe, knowing everything they need, and improving consumer engagement through intuitive user experiences. 

Preimplantation Genetic Testing Market: Trends and Developments

 Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.

The global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605

 By type, the preimplantation genetic screening segment accounted for the largest share of the market. The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.

The aneuploidy segment is expected to grow at the fastest CAGR. Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening. Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).

Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. 

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=605

As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others. 

Ophthalmic Surgical Instruments Market to Witness Steady Growth in the Near Future

 

Growth in this market is attributed to the rapid growth in the geriatric population, increasing number of ophthalmic surgeries owing to the rising prevalence of eye diseases, technological advancement in ophthalmic surgical instruments, and government initiatives to increase awareness about visual impairment across the globe.

The global Ophthalmic Surgical Instruments Market is projected to reach USD 11.18 Billion by 2022 from USD 8.36 Billion in 2017, at a CAGR of 6.0%. 

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11819932 

Based on product, the ophthalmic surgical instruments market is segmented into cataract surgery devices, vitreoretinal surgery devices, refractive surgery devices, glaucoma surgery devices, ophthalmic microscopes, and accessories. The cataract surgery devices segment accounted for the major share of the global ophthalmic surgical instruments market. The large share of this segment can primarily be attributed to the growing number of cataract surgeries across the globe. Glaucoma surgery devices segment is expected to register the highest growth during the forecast period. 

On the basis of refractive surgery devices, the ophthalmic surgical instruments market is segmented into femtosecond lasers, excimer lasers, other lasers, and refractive surgery instruments & kits. The femtosecond lasers segment accounted for the major share of the refractive surgery devices market and is also expected to register the highest CAGR during the forecast period. The large share and high growth of this segment is attributed to its benefits such as lower incidence of dry eyes, less induced aberrations, greater safety, faster uncorrected visual acuity recovery, less intraocular pressure (IOP) variation in the femtosecond-created flap, and growing number of femtosecond laser-assisted surgeries being performed across the globe.

On the basis of vitreoretinal surgery devices type, the ophthalmic surgical instruments market is segmented into vitreoretinal packs, vitrectomy machines, photocoagulation lasers, illumination devices, vitrectomy probes, and vitreoretinal surgery instruments & kits.

North America accounted for the largest share of the ophthalmic surgical instruments market in 2016, followed by Europe. 

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=11819932

The prominent players in the ophthalmic surgical instruments market are Alcon (Switzerland), Carl Zeiss Meditec (Germany), Johnson & Johnson Vision Care (US), Hoya Corporation (Japan), Bausch + Lomb (US), NIDEK (Japan), Topcon Corporation (Japan), Ellex Medical Lasers (Australia), IRIDEX Corporation (US), Lumenis (Israel), STAAR Surgical Company (US), and Ziemer Ophthalmic Systems (Switzerland).

Nucleic Acid Isolation and Purification Market: Trends and Developments

 The growth of this market can mainly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. On the other hand, the high cost of automated instruments is expected to hinder the growth of the market.

The global Nucleic Acid Isolation and Purification Market is projected to reach USD 4.8 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 8.9% during the forecast period. 

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229978287

On the basis of product, the nucleic acid isolation and purification market has been segmented into kits, reagents, and instruments. The kits segment accounted for the largest share of the global nucleic acid isolation and purification market in 2019. Growth in this market can be attributed to the low cost and easy usage of kits in applications such as gene sequencing, molecular diagnostics, and gene cloning.

On the basis of application, the global nucleic acid isolation and purification market is segmented into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. In 2019, the diagnostics segment accounted for the largest share of the global nucleic acid isolation and purification market; this segment is also expected to register the highest CAGR during the forecast period.

On the basis of type, the global nucleic acid isolation and purification market is segmented into plasmid DNA isolation and purification, total RNA isolation and purification, circulating nucleic acid isolation and purification, genomic DNA isolation and purification, messenger RNA isolation and purification, microRNA isolation and purification, PCR cleanup, and other nucleic acid isolation and purification types. In 2019, the plasmid DNA isolation segment accounted for the largest share of the market. 

In 2019, North America accounted for the largest share of the nucleic acid isolation and purification market, followed by Europe.

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=229978287

QIAGEN N.V. (Netherlands), Thermo Fisher Scientific (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are the key players operating in the nucleic acid isolation and purification market. 

 

Ophthalmic Equipment Market : Trends and Developments

The growing number of people with eye diseases, technological advancement in ophthalmic equipment, and the rising adoption of contact lenses and spectacles across the globe are the major factors driving the growth of this market.

The Ophthalmic Equipment Market is projected to reach USD 65.8 Billion by 2027 from USD 56.4 Billion in 2022, at a CAGR of 3.1% during the forecast period. 

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155637364

Based on diagnostic and monitoring devices type, the ophthalmic equipment market is segmented into optical coherence tomography (OCT) scanners, ophthalmic ultrasound imaging systems, fundus cameras, ophthalmoscopes, retinoscopes, wavefront aberrometers, corneal topography systems, autorefractors and keratometers, phoropters, specular microscopes, perimeter/visual field analyzers, tonometers, slit lamps, lensmeters, optical biometry systems, and chart projectors. The OCT scanners segment accounted for the major share of the ophthalmology diagnostic and monitoring devices market and this segment is expected to register the highest growth during the forecast period. 

On the basis of ophthalmology surgical devices type, the ophthalmic equipment market is segmented into cataract surgical devices, glaucoma surgical devices, refractive surgical devices, vitreoretinal surgical devices, ophthalmic microscopes, and accessories. The cataract surgical devices segment accounted for the major share of the ophthalmology surgical devices market. The large share of this segment is majorly attributed to the growing number of eye disorders in the geriatric population. 

North America is expected to account for the largest share of the ophthalmic equipment market in 2022, followed by Europe. The large share of this region is attributed to the presence of developed healthcare systems in the US & Canada, increasing number of eye disorders along with rising aging population, and availability of technologically advanced ophthalmic devices.

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=155637364

The prominent players in the ophthalmic equipment market are Essilor (France), Alcon (Switzerland), Johnson & Johnson Vision Care (US), Bausch + Lomb (US), Haag-Streit (Switzerland), TOPCON (Japan), Carl Zeiss Meditec (Germany), NIDEK (Japan), STAAR Surgical (US), HOYA (Japan), and Ziemer Ophthalmic Systems (Switzerland)

360quadrants Releases Quadrant on Best E-Commerce Platforms

 E-commerce platforms are a tech framework that help company owners control their selling activities digitally. Several market vendors provide various platforms of ecommerce to match various business needs. Each platform has its own benefits and drawbacks, and companies choose the one that fits their needs. E-commerce platforms typically represent the front end aspect of a company and facilitates online selling of goods to the customers. 

 360Quadrants, the most granular comparison platform, has released a quadrant on Best E-Commerce Platforms to help businesses make quicker and more informed decisions. Quadrants are generated post analysis of companies (product portfolios and business strategies) and will be updated every three months based on market and regional analyses and developments in the E-Commerce Platforms space. 360Quadrants conducts an in-depth SWOT analysis and accurately analyzes the companies considered for evaluation. This helps service providers in learning about new opportunities and areas where they lag behind their peers. It also helps clients in choosing the most appropriate vendor for their requirements. 

 

Know More: - https://www.360quadrants.com/software/e-commerce-platforms

 

Categorization of E-commerce Platform Providers 

 

360Quadrants evaluated over 35 companies in the E-Commerce Platforms space out of which 19 companies were categorized as Visionary Leaders, Innovators, Dynamic Differentiators, and Emerging Companies. 

 

Shopify, WooCommerce, BigCommerce, and Ecwid have been identified as visionary leaders as they have established product portfolios and a robust market presence and business strategies. 

Shopmatic, Zepo, Zoey, Ecomchain, and Storm have been identified as innovators as they have focused product portfolios, and innovative business strategies which help them in growing consistently.  

 

Digital River, Handshake, Kartrocket, and Teespring have been identified as emerging companies as they have niche product offerings and decent business strategies. 

2Checkout, Paypro Global, Square E-Commerce, nopCommerce, Sellfy, and Prestashop have been recognized as dynamic differentiators as they are largely dependent on their competitive R&D activities. 

 

360 Scoring Methodology 

Best Companies in E-Commerce Platforms will be rated using the following methodology – 

 

1.               A highly experienced team of researchers and senior analysts conduct extensive research to generate a list of vendors (competitors). 

2.               A patent-pending algorithm is used to collect inputs from key stakeholders—industry experts, buyers, vendors, and 360Quadrants analysts—based on criteria for Product Maturity and Company Maturity. 

a.   Criteria under Product Maturity include breadth and depth of product/service offering, product features and functionalities, product differentiation, and their impact on customer value. 

b.   Criteria under Company Maturity include geographical footprint, partner ecosystem, financial stability, and client coverage or sector footprint. 

3.               Approximately 100+ in-depth parameters will be considered for research for the best E-Commerce Platforms. These parameters will be updated every six months to ensure latest developments are taken into consideration. 

4.               A weightage is assigned to each stakeholder based on information gathered pertaining to the above criteria as well as inputs from stakeholders. These inputs follow the order of priority given below: 

a.   Buyers 

b.   Industry Experts  

c.    360Quadrants Analysts 

d.   Vendors (Competitors) 

5.               The inputs are analyzed, and a final rating is assigned to each vendor (competitor). 

6.                After the finalization of ratings, each vendor is placed in the most relevant quadrant based on their score. 

 

In Vitro Diagnostics Market : Emerging Trends and Developments

 

Factors such as increasing burden of chronic diseases (majorly due to the rising geriatric population), rising prevalence of infectious diseases, rising demand for early disease diagnosis using specialized tests, growing awareness on personalized medicine, increasing adoption of fully-automated instruments and automation in laboratories, and increasing adoption of point-of-care testing are driving the market growth. Moreover, the introduction of a new range of condition-specific markers and tests, with advances in genomics and proteomics, is expected to offer significant growth opportunities for market players during the forecast period.

The In Vitro Diagnostics Market is projected to reach USD 106.5 billion by 2027 from USD 68.1 billion in 2018, at a CAGR of 4.9%. 

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703

Based on applications, the IVD market is segmented into diabetes, infectious diseases, oncology, cardiology, nephrology, autoimmune diseases, drug testing/pharmacogenomics, HIV/AIDS, and other applications (neurological tests, endocrine tests, blood analysis tests, pregnancy tests, and general clinical applications). The infectious diseases segment accounted for the largest share of the IVD applications market in 2017. 

Based on technology, the in vitro diagnostics market is broadly divided into immunochemistry/immunoassay, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies (patient self-testing, point-of-care testing, lateral flow assays, and tissue processing). The immunochemistry/immunoassay segment is expected to dominate the market in 2018. 

Based on end user, the market is segmented into laboratories (large/reference laboratories, medium-sized laboratories, and small laboratories), hospitals, academic institutes, point-of-care testing, patient self-testing, and other end users. The point-of-care testing segment is expected to grow at the highest CAGR during the forecast period. The rising prevalence of infectious diseases in developing countries and increasing incidence of cardiac diseases and diabetes are the major factors driving the demand for POC tests. 

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America is expected to dominate the market followed by Europe. 

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=703 

The prominent players in the global in vitro diagnostics market include Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific (US), Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), DiaSorin (Italy), Ortho Clinical Diagnostics (US), Agilent Technologies (US), and QIAGEN (Germany).

New report examines the Infusion Pump Market worth $18.9 billion by 2025

The rising demand for ambulatory infusion pumps in home care settings, increasing incidence of chronic diseases along with the rapid growth of the geriatric population, and growing number of surgical procedures performed are the major factors driving the growth of this market.

The global Infusion Pump Market is projected to reach USD 18.9 billion by 2025 from USD 13.5 billion in 2020, at a CAGR of 7.0% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=90374506

Based on products, the infusion pumps market is segmented into accessories & consumables and devices. The accessories & consumables segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to its recurrent use and the increasing adoption of infusion pumps for the delivery of medications in a controlled environment.

Based on product, the infusion pumps market is segmented into dedicated accessories & consumables and non-dedicated accessories & consumables. The dedicated accessories & consumables segment is expected to grow at the highest CAGR during the forecast period.

Based on type, the infusion pump devices market has been segmented into traditional infusion pumps and specialty infusion pumps market. The specialty infusion pumps segment is expected to grow at the highest CAGR during the forecast period.

Based on application, the infusion pumps market is segmented into chemotherapy/oncology, diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, hematology, and other applications (includes infectious diseases, autoimmune diseases, and diseases of the heart, kidney, lung, and liver). The diabetes segment is expected to grow at the highest CAGR during the forecast period.

On the basis of end user, the infusion pumps market has been segmented into hospitals, home care settings, ambulatory care settings, and academic and research institutes. The home care settings segment is estimated to grow at the highest CAGR during the forecast period.

North America accounted for the largest share of the infusion pumps market in 2019, followed by Europe.

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=90374506

The prominent players in this market are Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Fresenius Kabi (Germany), ICU Medical, Inc. (US), Medtronic plc (Ireland), Micrel Medical Devices SA (Greece), and Ypsomed Holding AG (Switzerland), among other key players.

Report explores the High Throughput Screening Market worth $29.29 Billion by 2027

The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.

The High Throughput Screening Market is expected to reach USD 29.29 billion by 2027 from an estimated USD 14.95 billion in 2019, at a CAGR of 7.8%. 

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950

On the basis of product and service, the reagents & assay kits segment accounted for the largest share of the global HTS market. The large share of this segment can be attributed to factors such as the large numbers of reagents and assay kits used in HTS techniques, rising prevalence of a number of diseases, increasing pharmaceutical R&D, and increased government funding for life science research.

Based on technology, the HTS market is segmented into cell-based assays, lab-on-a-chip (LOC), ultra-high-throughput screening (uHTS), label-free technology, and bioinformatics. In 2018, the cell-based assays segment accounted for the largest share of the HTS market. The large share of this segment can be attributed to its increased use in cell culture techniques, especially 2D cell culture.

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the HTS market. Factors such as the increasing use of HTS techniques by pharmaceutical and biotechnology companies for drug discovery applications along with the increasing pharmaceutical R&D expenditure are driving the growth of this segment.

North America accounted for the largest share of the HTS market in 2018, followed by Europe and Asia Pacific. 

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=134981950

The prominent players in the global HTS market are Agilent (US), Danaher (US), Thermo Fisher Scientific (US), PerkinElmer (US), Tecan (Switzerland), Axxam (Italy), Merck Group (Germany), Bio-Rad (US), Hamilton (US), Corning (US), BioTek (US), and Aurora Biomed (Canada).

Lithotripsy Devices Market: Trends and Developments

 

Factors such as the growing incidence of urolithiasis and technological advancements in lithotripsy devices are driving the growth of this market.

The Lithotripsy Devices Market is expected to reach USD 1.76 Billion by 2023 from USD 1.41 Billion in 2018, at a CAGR of 4.5%.

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=29769904  

By type, the lithotripsy devices market is classified into extracorporeal shock wave lithotripsy devices and intracorporeal lithotripsy devices. In 2017, the extracorporeal shock wave lithotripsy devices segment accounted for the largest share of the market. ESWL is the least invasive of all stone treatments and is considered the treatment modality of choice for a majority of urinary stones.

On the basis of applications, the lithotripsy devices market is categorized into kidney stones, ureteral stones, pancreatic stones, and bile duct stones. In 2017, the kidney stones segment accounted for the largest share of the market. The increasing incidence of kidney stones and the recurrence of these stones over a period of time are the key factors driving the growth of this segment.

On the basis of end user, the lithotripsy devices market is categorized into hospitals, ambulatory surgical centers, and other end users. In 2017, the hospitals segment accounted for the largest share of the global lithotripsy devices market. 

Based on region, the lithotripsy devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America dominated the lithotripsy devices market in 2017.

Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=29769904

Some of the major players in the lithotripsy devices market are Siemens AG (Germany), Boston Scientific (US), Dornier MedTech (Germany), Olympus America (Japan), DirexGroup (Germany), and Richard Wolf (Germany).

Wearable Injectors Market to Witness Steady Growth in the Near Future

 The key factors driving the growth of this market are the growing prevalence of chronic diseases (such as cancer, diabetes, and cardiovascular diseases), favorable reimbursement scenario in major markets, and technological advancements in injector devices.

The global Wearable Injectors Market is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period (2018-2023).

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004

On the basis of type, the wearable injectors market is segmented into on-body and off-body injectors. The on-body injectors segment is expected to account for the larger market share in 2018, while the off-body injectors segment is projected to witness the highest growth rate during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.

On the basis of therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson’s disease, thalassemia, and primary immunodeficiency disorders). In 2018, the immune-oncology segment is expected to account for the largest share of the wearable injectors market. 

In 2018, North America is expected to account for the largest share of the wearable injectors market, followed by Europe. 

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=100771004 

The key players in the global wearable injectors market are Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutics Corporation (US), Valeritas (US), and SteadyMed Therapeutics (US). The other prominent players in this market are Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).

Laboratory Balances and Scales Market - Global Forecast to 2023

 

The major factors driving the growth of the laboratory balances and scales market are the technological advancements in laboratory balances and scales; increasing research investments and activities among pharma-biotech companies and CROs; increasingly stringent regulatory framework for product safety in bio-pharmaceutical industries; implementation of stringent food safety guidelines; and emerging markets.

The global Laboratory Balances and Scales Market is projected to reach USD 1.6 billion by 2023 from USD 1.3 billion in 2018, at a CAGR of 3.7%.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=166668097

Based on product type, the laboratory balances market is segmented into micro & ultra-micro balances, top loading/precision balances, analytical balances, portable/compact balances, moisture analyzers, and other balances. The analytical balances segment is expected to account for the largest share of the laboratory balances and scales market in 2018. The increasing adoption of analytical balances among biopharmaceutical industries, owing to its procedural benefits (such as portability, easy to operate, less weighing time, high durability, low cost, and high precision) is the major factor driving the growth of this market segment.

Based on product type, the laboratory scales market is segmented into bench scales, counting scales, compact scales, and other scales. The bench scales segment is expected to witness high growth rate in the laboratory scales market in 2018. The increasing adoption of laboratory scales among bio-pharmaceutical industry due to the procedural benefits offered by these instruments, such as flow-thru design ensures protection from liquids, touchless sensors, minimum stabilization time, ease of handling, and fast measurement time is the major factor driving the growth of this market segment.

Based on end user, the laboratory balances and scales market is segmented into pharmaceutical, cosmeceutical, and biotechnology product testing laboratories; chemical and material testing laboratories; food and beverage testing laboratories; petroleum product testing laboratories; research laboratories & academic institutes, and other end users. 

The laboratory balances and scales market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. 

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=166668097

The major players operating in the laboratory balances and scales market are A&D Company, Ltd (Japan), Metler Toledo international, Inc. (US), Sartorius AG (Germany), Shimadzu Corporation (Japan), PCE Instruments (UK), Kern & Sohn GmbH (Germany), RADWAG Balances and Scales (Poland), Adam Equipment Co. (UK), Avery Weigh-Tronix, LLC (UK), Bonso Electronics International, Inc. (China), Essae Group (India), and Gram Precision S.L (Spain).

Future Growth of Molecular Quality Controls Market worth $237 million by 2024

 

Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.

The  Molecular Quality Controls Market is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period. 

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523

Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls. The independent controls segment accounted for a larger share of the molecular controls market in 2018. The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.

By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls. Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.

While North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The presence of emerging economies such as China and India and the significant demand for high-quality and accurate diagnostic tests from the large patient population in this region are the major factors supporting the growth of the Asia Pacific molecular quality controls market.

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=82625523

The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).